ArticleNature biotechnology2026
Lipid nanoparticle screening in nonhuman primates with minimal loss of life.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Barcoded oligonucleotide system (BOLT) for targeted organ delivery.Bioactive materials · 2027Article
- Toward precision oncology: deciphering the circRNA-EMT axis in cancer and its therapeutic implications.RNA biology · 2026Review
- New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Non-invasive nanoparticle barcoding in nonhuman primates.Nature biotechnology · 2026Article
- Sequence-defined polymers for predictable gene delivery.Nature reviews. Chemistry · 2026Review
- CD39 mRNA therapy attenuates localized acute inflammation: A novel anti-inflammatory strategy using cationic nanoliposomes.Molecular therapy. Nucleic acids · 2026Article
- Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.American journal of human genetics · 2026Review
- Lipid nanoparticle screening in nonhuman primates with minimal loss of life.Nature biotechnology · 2026Article
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- Deciphering the biological fate of mRNA-LNP-based biologics: A perspective from tissue to intracellular distribution.Acta pharmaceutica Sinica. B · 2026Review
- Controlling In Vitro mRNA Polyadenylation by Monitoring Poly(A) Polymerase Consumption of ATP.International journal of molecular sciences · 2026Article
- High-Throughput In Vivo Screening Using Barcoded mRNA Identifies Lipid Nanoparticles With Extrahepatic Tropism for In Situ Immunoengineering.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Gene regulation by non-Coding RNAs in infertility: a mechanistic review.Journal of ovarian research · 2025Review
- High-Throughput Strategies for Streamlining Lipid Nanoparticle Development Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Microfluidic Device Type Improves Heart mRNA DeliveryLangmuir : the ACS journal of surfaces and colloids · 2025Article
- Intelligent Nanomedicine Systems Utilizing Diverse Nanoparticles for Osteosarcoma Therapy: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding how well delivery in mice predicts delivery in nonhuman primates (NHPs) could make lipid nanoparticle (LNP) discovery more efficient. Yet, few LNP-mRNA drug candidates are tested in NHPs, in part because the experiments require more animals than is considered ethical. Here, to minimize animal use, we create a pool of sterile barcoded LNPs that are frozen, aliquoted and administered when an end-of-life NHP-an animal that is independently scheduled for euthanasia due to spontaneous disease-becomes available. We then administer this pool of 45 LNP-aVHH mRNAs with different chemistries intravenously to mice and NHPs and observe a higher amount of aVHH expression in NHPs than in mice. We characterize systemic physiological responses to LNP treatment using 47 clinically relevant variables and analyze the transcriptomic response alongside delivery in single cells from three tissues in vivo. These data suggest that multiple lipoprotein receptors may be associated with delivery. Altogether, end-of-life NHPs reduce animal use and may be informative preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.